Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.03. | FY2029 EPS Estimates for GH Research Raised by HC Wainwright | 1 | MarketBeat | ||
03.03. | Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 | 3 | Insider Monkey | ||
01.03. | GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 | 1 | Insider Monkey | ||
27.02. | GH Research PLC - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
GH RESEARCH Aktie jetzt für 0€ handeln | |||||
27.02. | GH Research PLC: GH Research Reports Full Year 2024 Financial Results and Provides Business Updates | 99 | GlobeNewswire (Europe) | Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate... ► Artikel lesen | |
27.02. | GH Research PLC - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
27.02. | GH Research PLC - 6-K, Report of foreign issuer | - | SEC Filings | ||
26.02. | Stifel raises GH Research stock target to $32 on strong trial data | 1 | Investing.com | ||
13.02. | Cantor Fitzgerald sets GH Research stock Overweight, $14 target | 3 | Investing.com | ||
06.02. | GHRS Stock Rallies 55% in a Week: Here's What You Should Know | 2 | Zacks | ||
05.02. | GH Research prices $150M stock offering | 4 | Seeking Alpha | ||
05.02. | GH Research Prices Public Offering Of 10 Mln Shares At $15.00/shr | 2 | RTTNews | ||
05.02. | GH Research PLC: GH Research Announces Pricing of $150 Million Public Offering | 1 | GlobeNewswire (USA) | ||
04.02. | GH Research (NASDAQ:GHRS) Shares Gap Up - Should You Buy? | 1 | MarketBeat | ||
04.02. | GH Research leaps on psychedelic data in depression | - | pharmaphorum | ||
04.02. | H.C. Wainwright maintains buy on GH Research stock, $40 target | 2 | Investing.com | ||
04.02. | Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025 | 1 | Insider Monkey | ||
03.02. | GH Research stock target raised to $42 at Rodman & Renshaw | 2 | Investing.com | ||
03.02. | GH Research commences public offering of $150M of shares | 2 | Seeking Alpha | ||
03.02. | GH Research PLC: GH Research Announces Proposed Public Offering | 2 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,170 | +1,82 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
VALNEVA | 3,172 | +2,26 % | Valneva Aktie: Erwartungshaltung gegenüber dem Markt | News von Trading-Treff.de Die Biotechnologiefirma Valneva SE hat einen Prospekt bei der US-amerikanischen Wertpapieraufsichtsbehörde SEC eingereicht, der dem Unternehmen ermöglicht, bis zu 350 Millionen... ► Artikel lesen | |
BIOFRONTERA | 2,405 | +5,71 % | Top-Zock 2025: Formycon, Biofrontera oder BB Biotech? | Auf der Suche nach unserem Top-Zock 2025 haben wir unzählige Small- und Nano-Cap-Titel analysiert. Ein Wert sticht dabei mit einem überragenden Chance-Risiko-Profil über die nächsten Monate heraus.... ► Artikel lesen | |
BIOGEN | 125,75 | -0,63 % | European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen | ||
ILLUMINA | 73,84 | +0,64 % | Illumina Announces Board Changes: Scott Gottlieb Appointed Chair, Keith Meister Joins | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), an American biotechnology company, Tuesday has announced changes to its Board of Directors. Scott Gottlieb, MD, who has been a board member since... ► Artikel lesen | |
NANOREPRO | 1,545 | +2,66 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.03.2025 / 16:00... ► Artikel lesen | |
OCUGEN | 0,650 | -0,54 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
VAXART | 0,369 | -5,04 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
CYTODYN | 0,200 | +0,50 % | CytoDyn Inc.: March 2025 Letter to Shareholders | VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. ("CytoDyn" or the "Company"). On February 24... ► Artikel lesen | |
IMMUNIC | 1,018 | +0,99 % | EQS-News: Immunic AG: Immunic, Inc. to Participate in Scientific and Industry Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
01.04.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
CEL-SCI | 0,215 | +1,23 % | CEL-SCI Aktie: Rückenwind an der Börse! | Das Biotechnologieunternehmen sichert sich 2,56 Millionen Dollar für Krebsimmuntherapie Multikine und erhält positive Signale der FDA zum statistischen Analyseplan. Die CEL-SCI Corporation, ein Biotechnologieunternehmen... ► Artikel lesen | |
ADAPTIVE BIOTECHNOLOGIES | 6,830 | -0,52 % | Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions | New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment... ► Artikel lesen | |
BLUEPRINT MEDICINES | 81,04 | -0,98 % | Blueprint Medicines Aktie: Strategische Entscheidungen erklärt | Die Aktie des Präzisionstherapie-Unternehmens Blueprint Medicines verzeichnete am 22. Februar einen leichten Rückgang um 0,02% auf 88,18 EUR. Das Biotech-Unternehmen mit einer Marktkapitalisierung von... ► Artikel lesen | |
MUSTGROW BIOLOGICS | 0,662 | +6,09 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
GENPREX | 1,820 | -100,00 % | Genprex, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |